SYNAIRGEN PLC

Report Publication Announcement • Nov 12, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4335F

Synairgen plc

12 November 2015

PRESS RELEASE

12 November 2015

SYNAIRGEN PLC

("Synairgen" or "the Company")

Directors' Share Purchase

Southampton, UK, 12 November 2015: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, was informed that on 11 November 2015 the following Directors acquired ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 23p per Ordinary Share as follows:

		Interest before purchase		Interest after purchase
Director	Title	Number of Ordinary Shares	Number of Ordinary Shares acquired	Number of Ordinary Shares	% of total issued share capital
Richard Marsden	CEO	110,972	43,460	154,432	0.17%
Dr Philip Monk	CSO	161,710	21,729	183,439	0.20%
John Ward	FD	243,912	32,594	276,506	0.30%
Simon Shaw (Note 1)	Chairman	1,408,879	65,217	1,474,096	1.61%

Note 1 Simon Shaw's shareholding includes 105,516 Ordinary Shares held in his pension plan.

ENDS

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, James Thompson (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

[email protected]

Tel: +44 (0) 20 3709 5701

Notes for Editors

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma, COPD and severe lung disease, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSGGGBCGUPAPPG